

INFORME DE BÚSQUEDA DE PATENTES

Nº de solicitud: **NC20170010052**

CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boléanos utilizados**)

Palabras clave utilizadas	process for the preparation; carboxamide structured; androgen receptor (AR) antagonists; N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Cancer; Prostate cancer;
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA	CIP: C07D 403/12, C07D 207/32, C07D 207/34. CPC (Opcional):

DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)

Informes/Base de datos	Nº de solicitud/ Autor*	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (con indicación, si procede, de las partes relevantes)	Categoría especiales de los documentos citados**
ESPACENET, USPTO, Patbase, ORBIT y EPOQUENET	WO2012143599	26/Octubre/2012	1 a 26, 28, 29 y 31 Nivel Inventivo	Y
	Gniado K et al	2016	No afecta	A
	Chavan R	2016	No afecta	A

** Categorías especiales de documentos citados:

“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.	“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.
--	--

Literatura no patente

*Se incluye entre otros, toda la referencia de la literatura no patente.

Fecha del reporte de búsqueda:

07/12/2018

ORBIT

Erase all Save entire strategy Create a script Export																																															
Menu Explorer Searches - Easy search - Advanced search - Semantic search - Assignee search - Number search - My session Patent family searches (FamPat) <table> <thead> <tr> <th>Search Step</th><th>Result(s)</th><th>Query</th><th>Assistant</th><th>Source</th><th>Action</th></tr> </thead> <tbody> <tr> <td>6</td><td>42</td><td>5 AND (PROSTATE)</td><td>Search history</td><td>FAMPAT</td><td>Show results Modify Save Alert Delete</td></tr> <tr> <td>5</td><td>73</td><td>4 AND CANCER</td><td>Search history</td><td>FAMPAT</td><td>Show results Modify Save Alert Delete</td></tr> <tr> <td>4</td><td>80</td><td>CARBOXAMIDE AND 3</td><td>Search history</td><td>FAMPAT</td><td>Show results Modify Save Alert Delete</td></tr> <tr> <td>3</td><td>745</td><td>1 AND 2</td><td>Search history</td><td>FAMPAT</td><td>Show results Modify Save Alert Delete</td></tr> <tr> <td>2</td><td>11987</td><td>(ANDROGEN AND RECEPTOR AND ANTAGONIST)/BI/SA/KEY/IN/PA</td><td>Easy search</td><td>FAMPAT</td><td>Show results Modify Save Alert Delete</td></tr> <tr> <td>1</td><td>619356</td><td>(PROCESS S PREPARATION)/BI/SA/IN/PA</td><td>Easy search</td><td>FAMPAT</td><td>Show results Modify Save Alert Delete</td></tr> </tbody> </table>						Search Step	Result(s)	Query	Assistant	Source	Action	6	42	5 AND (PROSTATE)	Search history	FAMPAT	Show results Modify Save Alert Delete	5	73	4 AND CANCER	Search history	FAMPAT	Show results Modify Save Alert Delete	4	80	CARBOXAMIDE AND 3	Search history	FAMPAT	Show results Modify Save Alert Delete	3	745	1 AND 2	Search history	FAMPAT	Show results Modify Save Alert Delete	2	11987	(ANDROGEN AND RECEPTOR AND ANTAGONIST)/BI/SA/KEY/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete	1	619356	(PROCESS S PREPARATION)/BI/SA/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
Search Step	Result(s)	Query	Assistant	Source	Action																																										
6	42	5 AND (PROSTATE)	Search history	FAMPAT	Show results Modify Save Alert Delete																																										
5	73	4 AND CANCER	Search history	FAMPAT	Show results Modify Save Alert Delete																																										
4	80	CARBOXAMIDE AND 3	Search history	FAMPAT	Show results Modify Save Alert Delete																																										
3	745	1 AND 2	Search history	FAMPAT	Show results Modify Save Alert Delete																																										
2	11987	(ANDROGEN AND RECEPTOR AND ANTAGONIST)/BI/SA/KEY/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete																																										
1	619356	(PROCESS S PREPARATION)/BI/SA/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete																																										

Easy search

Menu Filter Explorer

42 results for 5 AND (PROSTATE) - Collection: FAMPAT

Filter options

1st application year

After 2015 (2)

2011-2015 (9)

2006-2010 (15)

2001-2005 (14)

Before 2001 (2)

More...

Assignee

ASTRAZENECA (11)

BAYER PHARMA (3)

BRISTOL MYERS SQUIBB (3)

ARRAY BIOPHARMA (2)

BAYER INTELLECTUAL PROPERTY (2)

More...

Litigations

Oppositions

Substituted thiophenes and uses thereof

WO2005016909 2004-08-12 ASTRAZENECA* ASTRAZENECA ACTIVORAG

This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

Process for the preparation of androgen receptor antagonists and intermediates thereof

CA2980965 2016-04-08 ORION*

The present invention relates to an improved process for the preparation of carboxamide structured androgen receptor (AR) antagonists such as N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (1A) and key intermediates thereof such as 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile (V). AR antagonists are useful in the treatment of cancer, particularly prostate cancer and other diseases where AR antagonism is desired.

A quinoline derivative acting as a p2x7-receptor antagonist

WO2009070116 2008-11-26 ASTRAZENECA*

The invention provides a compound of formula (I), a process for its preparation, pharmaceutical compositions containing it, a process for preparing the pharmaceutical composition, and its use in treatment of rheumatoid arthritis, inflammatory bowel disease or Crohn's disease.

Substituted thiophenes and uses thereof

Chemical structure: R5-O-C6H4-C5H2S-C(=O)NR1R2-NH-C(=O)NR3R4

USPTO

uspto

claims 1/5

Public Patent Application Information Retrieval

Patent eBusiness

Patent Application Information Retrieval

Global Dossier

Order Certified Application As Filed

Order Certified File Wrapper

View Order List

15/564,878

PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF

06267.0208-00000

Select New Case Application Data Transaction History Image File Wrapper Continuity Data Foreign Priority Published Documents Address & Attorney/Agent Assignments Display References

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Mail Room Date	Document Code	Document Description	Document Category	Page Count	PDF
10-01-2018	NOA	Notice of Allowance and Fees Due (PTOL-85)	PROSECUTION	9	☐
10-01-2018	892	List of references cited by examiner	PRIOR ART	1	☐
10-01-2018	FWCLM	Index of Claims	PROSECUTION	2	☐
10-01-2018	SRFW	Search information including classification, databases and other search related notes	PROSECUTION	1	☐
10-01-2018	IIFW	Issue Information including classification, examiner, name, claim, renumbering, etc.	PROSECUTION	3	☐
10-01-2018	1449	List of References cited by applicant and considered by examiner	PRIOR ART	1	☐
10-01-2018	BIB	Bibliographic Data Sheet	PROSECUTION	1	☐
07-20-2018	ELC	Response to Election / Restriction Filed	PROSECUTION	2	☐
07-20-2018	XT/	Extension of Time	PROSECUTION	1	☐
07-20-2018	WFEE	Fee Worksheet (SB06)	PROSECUTION	2	☐
07-20-2018	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐
04-12-2018	NTC.PUB	Notice of Publication	PROSECUTION	1	☐

ESPACENET

Cited in International search [ID] WO2012143599 (ORION CORP [FI], et al) [ID] 1-24 * steps a-f); page 69 - page 71; example 38 *

by applicant → WO2011051540

→ WO2012143599

EPOQUENET



New connection on: : 07-12-2018 : 14:07:12 - Last disconnection on: : 06-12-2018 : 17:51:49

V 4.0.0.44803(LP,U,linux) (Rev:43856 2017-04-27 09:03:29 +0200#(D201820)) (RPM D201820)

Welcome to EPOQUE Rebuild under the Production Environment

[No database/cluster active] ..FI EPODOC



Database: EPODOC

Records: 111.683.753

Terms: 1.479.122.018

Occurrences: 22.623.784.830

Last Update: 20181206

[EPODOC: SS 1] process AND for AND the AND preparation

Results in EPODOC **3**

[SS 2] androgen AND receptor AND antagonist+

Results in EPODOC **542**

[SS 3] PROCESS

Results in EPODOC **5.266.654**

[SS 4] 2 AND 3

Results in EPODOC **21**

[SS 5] caboxamide

Results in EPODOC 11

[SS 6] carboxamide

Results in EPODOC 16.395

[SS 7] 4 and 6

Results in EPODOC 5


[SS 8] ..li ti ab pn



1/5 © EPODOC / EPO

TI - **PROCESS** FOR THE PREPARATION OF **ANDROGEN RECEPTOR ANTAGONISTS** AND INTERMEDIATES THEREOF.

AB - The present invention relates to an improved **process** for the preparation of **carboxamide** structured **androgen receptor (AR) antagonists** such as N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3- **carboxamide** (1A) and key intermediates thereof such as 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile (V). **AR antagonists** are useful in the treatment of cancer, particularly prostate cancer and other diseases where AR antagonism is desired.




PN - [MX2017012910](#) A 20180115

2/5 © EPODOC / EPO

TI - **PROCESS** FOR THE PREPARATION OF **ANDROGEN RECEPTOR ANTAGONISTS** AND INTERMEDIATES THEREOF

AB - The present invention relates to an



improved **process** for the preparation of **carboxamide** structured **androgen receptor (AR) antagonists** such as N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3- **carboxamide** (1A) and key intermediates thereof such as 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile (V).


AR **antagonists** are useful in the treatment of cancer, particularly prostate cancer and other diseases where AR antagonism is desired.

PN - [CA2980965](#) A1 20161013

3/5 © EPODOC / EPO

TI - **Process** for the preparation of **androgen receptor antagonists** and intermediates thereof

AB - The present invention relates to an improved **process** for the preparation of **carboxamide** structured **androgen receptor (AR) antagonists** such as N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3- **carboxamide** (1A) and key intermediates thereof such as 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile (V). AR **antagonists** are useful in the treatment of cancer, particularly prostate cancer and other diseases where AR antagonism is desired.




PN - [CN107428695](#) A 20171201

4/5 © EPODOC / EPO

TI - **Process** for the preparation of **androgen receptor antagonists** and intermediates thereof

AB - The present invention relates to an improved **process** for the preparation



of **carboxamide** structured **androgen receptor (AR) antagonists** such as N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3- **carboxamide** (1A) and key intermediates thereof such as 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile (V).


AR **antagonists** are useful in the treatment of cancer, particularly prostate cancer and other diseases where AR antagonism is desired.

PN - [AU2016245278](#) A1 20171019

5/5 © EPODOC / EPO

TI - **PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF**

AB - The present invention relates to an improved **process** for the preparation of **carboxamide** structured **androgen receptor (AR) antagonists** such as N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3- **carboxamide** (1A) and key intermediates thereof such as 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile (V). AR **antagonists** are useful in the treatment of cancer, particularly prostate cancer and other diseases where AR antagonism is desired.



PN - [WO2016162604](#) A1 20161013

[SS 8]